Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;24(8):e757-e763.
doi: 10.1016/j.clbc.2024.09.002. Epub 2024 Sep 6.

Madarosis Among Breast Cancer Survivors

Sarah K Premji  1 , Kathryn J Ruddy  2 , Nicole Larson  3 , Charles L Loprinzi  2 , Brittany Dulmage  4 , Maryam Lustberg  5 , Fergus J Couch  6 , Janet E Olson  7 , Elizabeth Cathcart-Rake  2
Affiliations

Madarosis Among Breast Cancer Survivors

Sarah K Premji et al. Clin Breast Cancer. 2024 Dec.

Abstract

Background: Eyebrow and eyelash loss, known as madarosis, can occur after breast cancer-directed therapy. The purpose of this study was to ascertain the proportion of breast cancer survivors who experience madarosis, contributing factors, and associations between this symptom and quality of life.

Methods: Breast cancer survivors were invited to participate in an ongoing longitudinal cohort study as a part of the Mayo Clinic Breast Disease Registry (MCBDR). Consenting participants were mailed a survey approximately 1 year after diagnosis. The proportions of participants who reported eyebrow and eyelash loss were evaluated overall and according to treatment type. Quality of life (QOL) was also explored in this cohort.

Results: Eight hundred and thirty-eight breast cancer survivors responded to survey. The median age of survivors was 59.4 years (range 22-100 years), 315 (37%) had received chemotherapy (± endocrine therapy), 415 (50%) had received endocrine therapy only. Nearly half of participants reported eyebrow loss (49%) or eyelash loss (49%) that occurred after their diagnosis of breast cancer. Eyebrow loss was reported by 89% of chemotherapy recipients, by 27% of endocrine therapy only recipients, and by 19% of those not treated with either therapy. 102 (32%) of those with chemotherapy-associated eyebrow loss reported that it was complete. Eyelash loss was reported by 274 (87%) of chemotherapy recipients, 112 (27%) of endocrine therapy only recipients, and 23 (21%) of those who received neither therapy.

Conclusions: Madarosis is a common symptom in breast cancer survivors and future investigation into the predictors and treatment of madarosis is needed.

Keywords: Breast cancer treatment; Chemotherapy; Endocrine therapy; Eyebrow loss; Eyelash loss; Mental health.

PubMed Disclaimer

References

    1. Cancer.Net. Breast Cancer Statistics
    1. Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50(3):225–229. doi: 10.1093/jjco/hyz213 - DOI - PubMed
    1. Senna M, Ko J, Glashofer M, et al. Predictors of QOL in Patients with Alopecia Areata. Journal of Investigative Dermatology 2022; 142: 2646–2650.e2643. DOI: 10.1016/j.jid.2022.02.019. - DOI - PubMed
    1. Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–728. doi: 10.1001/jamadermatol.2018.5071 - DOI - PMC - PubMed
    1. Starace M, Cedirian S, Alessandrini AM, et al. Impact and Management of Loss of Eyebrows and Eyelashes. Dermatol Ther (Heidelb). 2023;13(6):1243–1253. doi: 10.1007/s13555-023-00925-z - DOI - PMC - PubMed